Syndax Pharmaceuticals (SNDX) Gross Margin (2024 - 2026)

Syndax Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 81.74% for Q1 2026.

• On a quarterly basis, Gross Margin fell 1385.0% year-over-year to 81.74% in Q1 2026; TTM through Mar 2026 was 98.07%, a 199.0% increase from a year earlier, with the FY2025 full-year figure at 95.96%, down 56.0% from the prior year.
• Gross Margin retreated to 81.74% in Q1 2026 per SNDX's latest filing, from 125.05% in the prior quarter.
• Across five years, Gross Margin topped out at 125.05% in Q4 2025 and bottomed at 81.74% in Q1 2026.
• The 3-year median for Gross Margin is 96.11% (2025), against an average of 96.27%.
• Biggest YoY gain for Gross Margin was 3580 bps in 2025; the steepest drop was 1806 bps in 2025.
• Year by year, Gross Margin stood at 89.24% in 2024, then jumped by 40 bps to 125.05% in 2025, then tumbled by 35 bps to 81.74% in 2026.
• Per Business Quant, the three latest SNDX Gross Margin figures stand at 81.74% (Q1 2026), 125.05% (Q4 2025), and 81.94% (Q3 2025).